In This Section

Cell and Gene Therapy Clinical Training Program

AddtoAny
Share:

Children's Hospital of Philadelphia's Cell and Gene Therapy Clinical Training Program provides targeted training on the processes required to take a research concept related to cell and gene therapy from the bench to patients by addressing knowledge gaps and potential barriers for individuals that are currently involved or interested in these areas. This program leverages our unique ability to focus on the benefits of cell and gene therapy in pediatric health, with a goal of positioning CHOP to be at the forefront of training the next generation of leaders in this scientific space with the tools to execute gene therapy programs. Physician fellows, postdoctoral fellows, and instructors with interest in clinical training are welcome to apply for this unique training experience.

The Cell and Gene Therapy Clinical Training Program content is developed and taught by CHOP faculty and Penn's Institute for Translational Medicine and Therapeutics (ITMAT) Regulatory program faculty. The program is designed for individuals who will benefit from developing a foundational knowledge of cell and gene therapy concepts coupled with an understanding of how to move a project through the various stages of development therapy.

  • Nine-month training program comprised of didactic and experiential components in partnership with the Raymond G. Perelman Center for Cellular and Molecular Therapeutics and Perelman Medical School's ITMAT Regulatory program
  • Delivers foundational knowledge of cell and gene therapy concepts coupled with an understanding of how to move a project through the various stages of development
  • Provides firsthand exposures and mock sessions for the PRE-IND, regulatory, and auditing processes
  • Offers opportunities to shadow current leaders in cell and gene therapy
  • Program meets January - May 2020 on Tuesdays from 8 am - 9 am and Wednesdays from 9 am - 12 pm
  • Shadowing occurs between May and September with a flexible schedule.

Phase 1: Didactic Component | January – May

Immersive instruction covering topics such as: Gene Editing, Gene Therapy Vectors, FDA Guidance on Cell and Gene Therapies, Ethics and Patient Advocacy, Budgeting for Clinical Trials.

Phase 2: Experiential Component | May - September

Shadowing opportunities in areas covering: Lentivirus, CAR T-cell Therapy, Adeno-Associated Virus (AAV) Vectors, and Antisense Oligonucleotide (ASO) Therapy.

  • Applicants must be a current physician fellow, postdoctoral fellow, or instructor at CHOP
  • Applicants must submit a completed application package (including a CV, brief personal statement, letter of recommendation, and signed mentor agreement form) by November 1, 2019